Topics

Articles

The company tested two different dosing regimens with one shown to be more effective.

The candidate BNT162b2 was shown to be 95 percent effective against COVID-19.

BNT162b2 showed 95 percent efficacy against COVID-19.

The latest vaccine candidate showed about 95 percent efficacy in a Phase 3 trial.

These new codes ensure physicians get paid for keeping their patients safe from COVID-19.

The candidate was shown to be more than 90 percent effective in preventing COVID-19 infection.

With infections on the rise at the start of flu season, the need for measures to limit transmission is as strong as ever.

The interim final rule with comment period would make the vaccine free to patients on Medicare and on most private health plans.

Concerns over efficacy and politics clouds hope for a vaccine to end the COVID-19 pandemic.

In an open letter, CEO Albert Bouria sought to give clarity to the drug’s development timeline.